MGC Pharmaceuticals Ltd
ASX:MXC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MGC Pharmaceuticals Ltd
Other Operating Expenses
MGC Pharmaceuticals Ltd
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MGC Pharmaceuticals Ltd
ASX:MXC
|
Other Operating Expenses
-AU$2m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-32%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Other Operating Expenses
-AU$6.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Other Operating Expenses
-AU$53.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Other Operating Expenses
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Other Operating Expenses
AU$9.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Other Operating Expenses
-AU$571k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
MGC Pharmaceuticals Ltd
Glance View
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).
See Also
What is MGC Pharmaceuticals Ltd's Other Operating Expenses?
Other Operating Expenses
-2m
AUD
Based on the financial report for Dec 31, 2023, MGC Pharmaceuticals Ltd's Other Operating Expenses amounts to -2m AUD.
What is MGC Pharmaceuticals Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 10Y
-32%
Over the last year, the Other Operating Expenses growth was 41%. The average annual Other Operating Expenses growth rates for MGC Pharmaceuticals Ltd have been 29% over the past three years , -23% over the past five years , and -32% over the past ten years .
